Drupal.behaviors.print = function(context) {window.print();window.close();}>
Quark to Run Phase IIa Trial of RNAi Drug in Glaucoma
May 03, 2012
Quark to Run Phase IIa Trial of RNAi Drug in Glaucoma
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Quark Still Sees IPO as a Possibility as Phase II Trials Near Completion
February 9, 2012 / Gene Silencing News
Quark Releases Positive Phase I Data on Ocular Neuroprotectant
January 12, 2012 / Gene Silencing News
RNAi Drugs Field Sees Candidate Failures as More Drugs Enter the Clinic
November 17, 2011 / Gene Silencing News
Lundbeck, Debiopharm Join List of Pharmas Looking to RNAi
February 3, 2011 / Gene Silencing News
Still Eyeing IPO, Quark Says Cost Expectations for Rx Pipeline Exceed $54M
January 27, 2011 / Gene Silencing News